B. Metzler seel. Sohn & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Other funds holding BMRN
B. Metzler seel. Sohn & Co's BMRN Position: Q4 2025 in Review
B. Metzler seel. Sohn & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,889 shares — an estimated $265K sold.
B. Metzler seel. Sohn & Co first reported a position in BMRN in Q4 2020 and held it in 20 quarters. The position peaked at $6.88M in Q4 2022. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- B. Metzler seel. Sohn & Co reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- B. Metzler seel. Sohn & Co sold 4,889 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $265K.
- B. Metzler seel. Sohn & Co first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 20 quarters.
- B. Metzler seel. Sohn & Co's BioMarin Pharmaceuticals position peaked at $6.88M in Q4 2022.
- 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2025, filed 28 Jan 2026.